Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development

PHILADELPHIA–(BUSINESS WIRE)–#HIV–Integral Molecular, the industry leader in engineering membrane
proteins, has extended its protein engineering capabilities to stabilize
viral proteins and produce more effective candidate vaccines against HIV
and other viruses.

The company’s protein engineering approach is based on its successful
high-throughput Shotgun Mutagenesis technology. Using this approach,
Integral Molecular can identify viral protein variants that have
improved stability but retain their native protein structures. This
strategy results in stabilized proteins that can elicit protective
immune responses.

In collaboration with researchers at Weill Cornell Medical College,
Integral Molecular developed stable trimeric HIV glycoproteins (Sullivan
et al., 2017 Journal of Virology). Using a combination of rational
design and empirical high-throughput screening, researchers created and
tested over 800 individual mutants of the HIV envelope protein in human
cells. Effective mutations were combined to produce an envelope
glycoprotein variant with improved stability and native-like

“The unstable nature of viral envelope glycoproteins has been a major
hurdle in the development of an effective vaccine against HIV and other
viruses,” said Benjamin Doranz, President and CEO of Integral Molecular.
“The high-throughput protein stabilization strategy developed here is a
groundbreaking step in developing more effective vaccines.”

About Integral Molecular

Integral Molecular (
is a research-driven biotechnology company creating a pipeline of
therapeutic antibodies against under-exploited membrane protein targets,
including GPCRs, ion channels, transporters, and viral envelope
proteins, using its proprietary MPS Discovery Engine®. This
platform is built on the company’s Lipoparticle and Shotgun Mutagenesis
technologies and over 15 years of experience optimizing membrane
proteins, enabling the isolation, characterization, and engineering of
monoclonal antibodies against otherwise intractable membrane protein
targets. Integral Molecular discovers antibodies for partners in
parallel with its own independent work developing antibodies for
licensing. The company currently has therapeutic programs focused on
pain, immunity, metabolic disorders, and infectious diseases.


Integral Molecular Inc.
Benjamin Doranz, President & CEO